Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation

Mutations in the NRAS gene are common alterations in malignant melanoma. However, there are no specific treatment options approved for NRAS-mutated melanoma patients besides immune checkpoint inhibition. Since preclinical data suggests a synergistic effect of a MEK inhibitor (MEKi) and the oncolytic...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Sonja C. S., Müller, Verena, Utikal, Jochen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027906/
https://www.ncbi.nlm.nih.gov/pubmed/36959781
http://dx.doi.org/10.3389/fonc.2023.1111119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027906/
https://www.ncbi.nlm.nih.gov/pubmed/36959781
http://dx.doi.org/10.3389/fonc.2023.1111119

Ejemplares similares